Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 iBio, CC-Pharming Expand Collaboration in China | Contract Pharma

What are you searching for?

Sign in

iBio, CC-Pharming Expand Collaboration in China

Licenses to iBio’s Bio-Better Rituximab and FastPharming™ System expand commercial partnership

By: Cassandra Gervolino

iBio, Inc. has expanded the scope of its business venture with CC-Pharming Ltd. by granting it an exclusive, royalty-bearing commercial license to iBio’s bio-better rituximab (iBio Rituximab) product candidates for the territory of China. In addition, the company will grant to CC-Pharming a research license to iBio’s FastPharming System and know-how for the evaluation of multiple product opportunities.
 
The companies are jointly pursuing the medical and business goal of introducing a bio-better rituximab that is more affordable in price to the Chinese market. Additionally, the companies plan to develop products other categories, particularly research and clinical reagents, non-pharmaceutical skincare products and botanical derivatives. iBio and CC-Pharming are currently evaluating the business feasibility of developing additional biopharmaceutical products for oncology, metabolic disorders, and fibrotic disease.
 
“We believe this is an important strategic relationship for both parties: it enables us to participate in the vast Chinese market using our existing assets, while CC Pharming uses our technology to provide China’s massive population with access to cost-effective critical drugs,” commented Robert B. Kay, iBio’s Chairman and CEO. “The expanded scope of our partnership with CC-Pharming aims first to advance our plant-derived, bio-better rituximab toward commercialization in the near term, while we jointly explore opportunities to develop and commercialize additional high value products.”
 
“iBio’s plant-based production technology is an elegant approach to biopharmaceutical manufacturing, particularly when applied to rituximab, one of the world’s top-selling drugs,” said Dr. Kevin Wang, CC-Pharming’s Chairman and Chief Scientific Officer. “China was a relative newcomer to the biopharmaceutical industry. With economic development, the country is becoming a top destination for complex biologics. The total value of China’s biopharma market reached $130 billion in 2018. iBio’s plant-based production system has the potential to produce biopharmaceuticals, as well as non-pharmaceutical products, in a more timely and cost-efficient manner, so we are excited to identify other opportunities to apply iBio’s technology.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters